Haemopoietic growth factors induce human basophil migration in vitro. 1992

M Yamaguchi, and K Hirai, and S Shoji, and T Takaishi, and K Ohta, and Y Morita, and S Suzuki, and K Ito
Department of Medicine and Physical Therapy, University of Tokyo School of Medicine, Japan.

Accumulation of basophils in inflammatory sites is an important aspect of the late-phase allergic reaction involving skin and upper and lower airways, suggesting the existence of mechanisms for basophil migration. Because haemopoietic growth factors have been shown to stimulate various functions of human basophils, we tested the ability of haemopoietic growth factors to migrate basophils in vitro. Both IL-3 and granulocyte-macrophage colony-stimulating factor (GM-CSF) induced migration of purified normal basophils (purity c. 80%) in a dose-dependent fashion at picomolar concentrations, while granulocyte (G)-CSF, macrophage (M)-CSF, and IL-4 had no effect at all. Chequerboard analyses indicate that migratory activity of both factors are chemokinetic. These results suggest that local production of both factors during allergic reactions might potentially play an initial role in the recruitment of basophils from the circulation to sites of inflammatory reactions.

UI MeSH Term Description Entries
D007377 Interleukin-3 A multilineage cell growth factor secreted by LYMPHOCYTES; EPITHELIAL CELLS; and ASTROCYTES which stimulates clonal proliferation and differentiation of various types of blood and tissue cells. Burst-Promoting Factor, Erythrocyte,Colony-Stimulating Factor 2 Alpha,Colony-Stimulating Factor, Mast-Cell,Colony-Stimulating Factor, Multipotential,Erythrocyte Burst-Promoting Factor,IL-3,Mast-Cell Colony-Stimulating Factor,Multipotential Colony-Stimulating Factor,P-Cell Stimulating Factor,Eosinophil-Mast Cell Growth-Factor,Hematopoietin-2,Burst Promoting Factor, Erythrocyte,Colony Stimulating Factor, Mast Cell,Colony Stimulating Factor, Multipotential,Eosinophil Mast Cell Growth Factor,Erythrocyte Burst Promoting Factor,Hematopoietin 2,Interleukin 3,Multipotential Colony Stimulating Factor,P Cell Stimulating Factor
D002464 Cell Migration Inhibition Phenomenon of cell-mediated immunity measured by in vitro inhibition of the migration or phagocytosis of antigen-stimulated LEUKOCYTES or MACROPHAGES. Specific CELL MIGRATION ASSAYS have been developed to estimate levels of migration inhibitory factors, immune reactivity against tumor-associated antigens, and immunosuppressive effects of infectious microorganisms. Chemotaxis Inhibition,Chemotaxis Inhibitions,Inhibition, Chemotaxis,Inhibitions, Chemotaxis
D002465 Cell Movement The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell. Cell Migration,Locomotion, Cell,Migration, Cell,Motility, Cell,Movement, Cell,Cell Locomotion,Cell Motility,Cell Movements,Movements, Cell
D002630 Chemotactic Factors Chemical substances that attract or repel cells. The concept denotes especially those factors released as a result of tissue injury, microbial invasion, or immunologic activity, that attract LEUKOCYTES; MACROPHAGES; or other cells to the site of infection or insult. Chemoattractant,Chemotactic Factor,Chemotaxin,Chemotaxins,Cytotaxinogens,Cytotaxins,Macrophage Chemotactic Factor,Chemoattractants,Chemotactic Factors, Macrophage,Macrophage Chemotactic Factors,Chemotactic Factor, Macrophage,Factor, Chemotactic,Factor, Macrophage Chemotactic
D002634 Chemotaxis, Leukocyte The movement of leukocytes in response to a chemical concentration gradient or to products formed in an immunologic reaction. Leukotaxis,Leukocyte Chemotaxis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000906 Antibodies Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).
D001491 Basophils Granular leukocytes characterized by a relatively pale-staining, lobate nucleus and cytoplasm containing coarse dark-staining granules of variable size and stainable by basic dyes. Basophil
D016178 Granulocyte-Macrophage Colony-Stimulating Factor An acidic glycoprotein of MW 23 kDa with internal disulfide bonds. The protein is produced in response to a number of inflammatory mediators by mesenchymal cells present in the hemopoietic environment and at peripheral sites of inflammation. GM-CSF is able to stimulate the production of neutrophilic granulocytes, macrophages, and mixed granulocyte-macrophage colonies from bone marrow cells and can stimulate the formation of eosinophil colonies from fetal liver progenitor cells. GM-CSF can also stimulate some functional activities in mature granulocytes and macrophages. CSF-GM,Colony-Stimulating Factor, Granulocyte-Macrophage,GM-CSF,Histamine-Producing Cell-Stimulating Factor,CSF-2,TC-GM-CSF,Tumor-Cell Human GM Colony-Stimulating Factor,Cell-Stimulating Factor, Histamine-Producing,Colony Stimulating Factor, Granulocyte Macrophage,Granulocyte Macrophage Colony Stimulating Factor,Histamine Producing Cell Stimulating Factor,Tumor Cell Human GM Colony Stimulating Factor
D016298 Hematopoietic Cell Growth Factors These growth factors comprise a family of hematopoietic regulators with biological specificities defined by their ability to support proliferation and differentiation of blood cells of different lineages. ERYTHROPOIETIN and the COLONY-STIMULATING FACTORS belong to this family. Some of these factors have been studied and used in the treatment of chemotherapy-induced neutropenia, myelodysplastic syndromes, and bone marrow failure syndromes. Hematopoietins,Hematopoietic Cell Growth Factor,Hematopoietic Stem Cell Stimulators,Hematopoietic Stem Cell-Activating Factors,Hematopoietic-CGF,Hematopoietic CGF

Related Publications

M Yamaguchi, and K Hirai, and S Shoji, and T Takaishi, and K Ohta, and Y Morita, and S Suzuki, and K Ito
April 1997, Postgraduate medical journal,
M Yamaguchi, and K Hirai, and S Shoji, and T Takaishi, and K Ohta, and Y Morita, and S Suzuki, and K Ito
June 1990, The Quarterly journal of medicine,
M Yamaguchi, and K Hirai, and S Shoji, and T Takaishi, and K Ohta, and Y Morita, and S Suzuki, and K Ito
May 1991, BMJ (Clinical research ed.),
M Yamaguchi, and K Hirai, and S Shoji, and T Takaishi, and K Ohta, and Y Morita, and S Suzuki, and K Ito
May 1988, The Medical journal of Australia,
M Yamaguchi, and K Hirai, and S Shoji, and T Takaishi, and K Ohta, and Y Morita, and S Suzuki, and K Ito
April 1989, British medical bulletin,
M Yamaguchi, and K Hirai, and S Shoji, and T Takaishi, and K Ohta, and Y Morita, and S Suzuki, and K Ito
May 2015, Clinical orthopaedics and related research,
M Yamaguchi, and K Hirai, and S Shoji, and T Takaishi, and K Ohta, and Y Morita, and S Suzuki, and K Ito
January 2014, BMC cancer,
M Yamaguchi, and K Hirai, and S Shoji, and T Takaishi, and K Ohta, and Y Morita, and S Suzuki, and K Ito
December 1989, Biochimica et biophysica acta,
M Yamaguchi, and K Hirai, and S Shoji, and T Takaishi, and K Ohta, and Y Morita, and S Suzuki, and K Ito
April 1989, Lancet (London, England),
M Yamaguchi, and K Hirai, and S Shoji, and T Takaishi, and K Ohta, and Y Morita, and S Suzuki, and K Ito
September 1992, Pharmacological research,
Copied contents to your clipboard!